---
title: "Anterix | 8-K: FY2027 Q1 Revenue Misses Estimate at USD 1.958 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295574607.md"
datetime: "2026-08-11T20:13:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295574607.md)
  - [en](https://longbridge.com/en/news/295574607.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295574607.md)
generator: "portal-rs"
---

# Anterix | 8-K: FY2027 Q1 Revenue Misses Estimate at USD 1.958 M

Revenue: As of FY2027 Q1, the actual value is USD 1.958 M, missing the estimate of USD 1.979 M.

EPS: As of FY2027 Q1, the actual value is USD 0.01, beating the estimate of USD -0.1653.

EBIT: As of FY2027 Q1, the actual value is USD -231 K.

### Financial and Operational Highlights

Anterix Inc. reported approximately $33.1 million in contracted proceeds outstanding, with over $15.7 million received from customers during the first quarter of fiscal year 2027 and an additional $9.6 million expected during the remainder of fiscal year 2027. The company entered into a 10 MHz 900 MHz spectrum license sale agreement with Benton PUD for a total contract price of $0.8 million on April 16, 2026. Anterix Inc. also recorded a $10.653 million gain on the exchange of broadband licenses after exchanging narrowband for broadband licenses in six counties. Investments in spectrum clearing costs amounted to $6.7 million. 

### Consolidated Statements of Operations (Three months ended June 30, 2026 vs. 2025)

#### Spectrum Revenue

-   **2026**: $1.958 million.
-   **2025**: $1.418 million.

#### Operating Expenses

-   **Total Operating Expenses**: $12.856 million in 2026, a decrease from $13.806 million in 2025.
-   **General and administrative expenses**: $9.624 million in 2026, down from $10.449 million in 2025.
-   **Sales and support expenses**: $1.911 million in 2026, up from $1.493 million in 2025.
-   **Product development expenses**: $1.220 million in 2026, up from $1.120 million in 2025.
-   **Severance and other related charges**: $0 in 2026, compared to $0.620 million in 2025.
-   **Depreciation and amortization**: $0.101 million in 2026, down from $0.124 million in 2025.

#### Other Income and Expenses

-   **Gain on exchange of intangible assets, net**: - $10.653 million in 2026, compared to - $33.916 million in 2025.
-   **Gain on sale of intangible assets, net**: $0 in 2026, compared to - $0.961 million in 2025.
-   **Loss from disposal of long-lived assets, net**: $0.001 million in 2026, down from $0.008 million in 2025.

#### (Loss) Income from Operations

-   **2026**: - $0.246 million.
-   **2025**: $22.481 million.

#### Interest Income

-   **2026**: $0.845 million.
-   **2025**: $0.442 million.

#### Other Income

-   **2026**: $0.015 million.
-   **2025**: $0.

#### Net Income

-   **2026**: $0.240 million.
-   **2025**: $25.180 million.

### Consolidated Statements of Cash Flows (Three months ended June 30, 2026 vs. 2025)

#### Net Cash Provided by (Used in) Operating Activities

-   **2026**: $2.045 million provided.
-   **2025**: - $3.140 million used.

#### Net Cash Used in Investing Activities

-   **2026**: - $6.739 million.
-   **2025**: - $2.665 million.

#### Net Cash Provided by (Used in) Financing Activities

-   **2026**: $19.951 million provided.
-   **2025**: - $0.642 million used.

#### Net Change in Cash and Cash Equivalents and Restricted Cash

-   **2026**: $15.257 million increase.
-   **2025**: - $6.447 million decrease.

#### Cash and Cash Equivalents and Restricted Cash at End of Period

-   **June 30, 2026**: $119.920 million.
-   **June 30, 2025**: $48.577 million.

### Liquidity and Balance Sheet (as of June 30, 2026)

Anterix Inc. reported no debt and held $116.0 million in cash and cash equivalents, along with a restricted cash balance of $3.9 million in escrow deposits. The company’s authorized share repurchase program allows for up to $250.0 million of common stock repurchases, with $226.7 million remaining available as of June 30, 2026; no share repurchase activity occurred in the first quarter of fiscal year 2027. 

### Consolidated Balance Sheets (as of June 30, 2026 vs. March 31, 2026)

#### Cash and cash equivalents

-   **June 30, 2026**: $116.010 million.
-   **March 31, 2026**: $98.533 million.

#### Total assets

-   **June 30, 2026**: $497.925 million.
-   **March 31, 2026**: $465.210 million.

#### Total liabilities

-   **June 30, 2026**: $212.131 million.
-   **March 31, 2026**: $202.889 million.

#### Total stockholders’ equity

-   **June 30, 2026**: $285.794 million.
-   **March 31, 2026**: $262.321 million.

### Related Stocks

- [ATEX.US](https://longbridge.com/en/quote/ATEX.US.md)

## Related News & Research

- [The Bull Case For Anterix (ATEX) Could Change Following ESOP Share Offering And Profitability Shifts](https://longbridge.com/en/news/296714283.md)
- [Top Executive Makes Bold Move With Major Anterix Stock Sale](https://longbridge.com/en/news/296167198.md)
- [Anterix CEO Scott Lang disposes of $3.17 million in common shares](https://longbridge.com/en/news/296145916.md)
- [EL: Full-year sales and margins rose, with 2027 guidance raised for both growth and profitability](https://longbridge.com/en/news/296341885.md)
- [Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock split](https://longbridge.com/en/news/296471274.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**